Dolsic: Main Uses and Benefits

Quick Facts

• May aid in the management of major depressive disorder.
• Used for the maintenance of stability in generalized anxiety disorder.
• Offers support for discomfort associated with diabetic peripheral neuropathic pain.
• Indicated for the relief of chronic discomfort from fibromyalgia.
• Contributes to the management of ongoing musculoskeletal discomfort.

---

Dolsic is a prescription medication used to address several distinct health concerns. It is primarily indicated for the management of major depressive disorder (MDD) in adults, a condition characterized by a prominent and persistent depressed mood that can interfere with daily function. The medication is also utilized to help maintain stability in generalized anxiety disorder (GAD).

Beyond mental health applications, Dolsic is associated with therapeutic benefit in several chronic pain conditions. It may aid in the management of discomfort stemming from diabetic peripheral neuropathic pain (DPNP), which is nerve-related discomfort linked to diabetes. The medication is also used to provide relief from the long-standing, widespread discomfort characteristic of fibromyalgia, and it contributes to the overall management of chronic musculoskeletal discomfort, including chronic low back pain and pain associated with osteoarthritis of the knee.

Eligibility Map: Who Can and Cannot Use Dolsic (Tramadol Hydrochloride)

The use of Dolsic (Tramadol Hydrochloride) is strictly regulated, defining specific populations who are permitted, restricted, or prohibited from using the medicine based on official governmental labeling.

Eligibility Scope

Classification	Population or Condition
Populations for whom use is allowed	Adults and adolescents 12 years of age and older (in the absence of contraindications).
Populations for whom use is not recommended	Patients with severe hepatic impairment or severe renal impairment; individuals who are pregnant or breastfeeding.
Populations for whom use is contraindicated	Children younger than 12 years of age (all uses).

Age and Condition-Specific Eligibility Rules

• Age-Related: Use is absolutely prohibited in children under 12 years and in those under 18 years following tonsillectomy or adenoidectomy. Use in adolescents (12–18 years) with existing respiratory risk factors should be avoided.
• Comorbidity: The medicine is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction, or uncontrolled epilepsy.
• Concomitant Therapy: Dolsic is contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI.

Connection to the overall eligibility profile Regulatory documents establish clear non-eligibility criteria based on patient age, the presence of specific comorbidities, and concurrent drug therapy. These restrictions are classified as either contraindications (absolute prohibition) or not recommended (high restriction) to strictly manage the population eligible for use.

Dolsic Interactions with other medicines and products

The official regulatory profile for Dolsic (Tramadol Hydrochloride) mandates specific restrictions due to documented interaction patterns. Co-administration is formally contraindicated with Monoamine Oxidase Inhibitors (MAOIs); use is prohibited within 14 days of discontinuing an MAOI due to the risk of severe, potentially life-threatening reactions. The use of Dolsic with any other Tramadol-containing product is also explicitly prohibited.

---

Exposure-Altering Interactions

The concurrent use of certain enzyme modulators officially alters Dolsic’s exposure. CYP2D6 and CYP3A4 Inhibitors (e.g., Quinidine, Ketoconazole) are documented to increase the plasma concentration of Tramadol or its active metabolite (M1), raising the risk of adverse effects. Conversely, CYP3A4 Inducers (e.g., Carbamazepine, Rifampin) are documented to decrease Tramadol exposure, which may reduce its efficacy.

---

Additive Risk Interactions

Combining Dolsic with substances affecting the central nervous system (CNS) results in an additive pharmacodynamic risk. CNS depressants, including alcohol, other opioids, and benzodiazepines, increase the risk of profound sedation and respiratory depression. Co-administration with Serotonergic Drugs (e.g., SSRIs, Triptans) officially increases the risk of Serotonin Syndrome. Herbal products such as St. John's Wort and supplements like Tryptophan are noted for their dual interaction potential. Extended-release formulations are restricted in patients with severe hepatic or renal impairment due to documented reduced clearance.

How Dolsic Works

The mechanism of Dolsic (Tramadol) is characterized by a unique dual action within the central nervous system (CNS), which influences the way the body handles nociceptive input.

Engagement of mu-Opioid Receptors by the Active Metabolite The drug's metabolite, O-desmethyltramadol (M1), binds to mu-opioid receptors ( OP3) on nerve cells. This engagement initiates an inhibitory cellular cascade that acts to modulate the transmission of nociceptive signals. The full physiological consequence of this effect is contingent upon the CYP2D6 enzyme, which is required to convert the parent drug into the M1 metabolite, a compound with high affinity for the receptor.

Enhancement of the Descending Pain Control Pathway The drug simultaneously inhibits the neuronal reuptake of the neurotransmitters Norepinephrine (NE) and Serotonin (5-HT). By increasing the availability of these chemicals, the drug enhances the activity of the body’s descending pain-inhibitory pathway, thereby influencing nociceptive signal propagation at the spinal cord level.

Physiological Consequence of Dual Modulation This dual mechanism—directly inhibiting nociceptive transmission (opioid action) and enhancing the intrinsic descending pain control system (monoamine action)—results in a complementary modulation of nociceptive signaling. This dual pharmacological approach produces a distinct physiological change characteristic of its combined mechanism.

How Dolsic (Tramadol Hydrochloride) is Used

The administration of Dolsic follows specific methods based on dosage form, frequency, and patient-specific needs. The medicine is primarily administered through the oral route (as tablets, capsules, or solution) and the parenteral route (intravenous, intramuscular, or subcutaneous injection).

Dosing and Administration Patterns

Use typically initiates with a titration schedule for the Immediate-Release (IR) oral form, starting as low as 25 mg once daily and increasing gradually. The standard maintenance dose for IR oral or parenteral administration ranges from 50 mg to 100 mg every four to six hours, with a total dose not to exceed 400 mg per day. Extended-Release (ER) formulations are taken once daily, starting at 100 mg, and have a lower maximum daily limit of 300 mg.

Administration instructions require that ER tablets and capsules must be swallowed whole and must not be crushed, chewed, split, or dissolved, as this can affect the rate of drug release. The medication may be taken with or without food.

Population-Specific Use Adjustments

Specific dose and interval adjustments are utilized for vulnerable populations. For patients over 75 years of age, or those with significant renal or hepatic impairment, the dosing interval may need to be extended to twelve hours, and the overall maximum daily dose for IR forms is typically reduced. In cases of severe impairment, ER formulations are not recommended. If a dose is missed, standard practice is to take it only if the next scheduled dose is not due for several hours, and never to double the dose.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has explored whether Dolsic investigated specific variables defined in the studies, such as measures of inflammatory response and pain markers. Overall, it is one of the approaches included in the research for conditions characterized by inflammation.

Clinical trials examined the measured parameters between groups, including a placebo group. Findings from these comparisons varied across different patient sub-groups. Furthermore, some studies have examined the drug's use in treatment-naïve populations to assess initial effects.

---

Mechanism of Action and Disease Activity

Pre-clinical and early clinical studies evaluated whether the drug influences key inflammatory pathways, such as the cyclooxygenase (COX) enzyme system, and whether this was associated with long-term changes in biomarkers/measured variables related to disease activity. Dolsic research suggests an influence on both COX-1 and COX-2 enzymes.

The scope of the research was focused on specific patient populations primarily dealing with moderate-to-severe inflammatory conditions or acute pain settings.

---

Combination Therapy Studies

Early phase research explored the potential combined effects with co-administered therapies. These initial studies were primarily designed to measure adverse events and tolerance of the combination rather than long-term outcomes.

Other studies examined whether the combination therapy was associated with changes in pain levels. Findings showed that a sub-group of patients experienced measurable changes in pain markers when compared to the reference group.

---

Safety Profile Research

Studies involving the drug generally included monitoring of liver function, and this data has been captured across various trials. Research reported that adverse event rates were comparable to other non-steroidal anti-inflammatory drugs (NSAIDs) in the same class in most published literature. Serious adverse events are monitored across all phases of research.

Research has examined the use of Dolsic in individuals with severe kidney impairment. Data on other specific high-risk groups were limited in the initial Phase 3 studies. This new combination measured adverse events and tolerance in adult populations.

Key Studies & References

1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) - StatPearls - NCBI Bookshelf
2. Oral Non-Steroidal Anti-Inflammatory (NSAID) - NHS GGC Guideline (Clinical Guidelines)

Common questions about Dolsic (FAQ)

Q: Does Dolsic treat depression?

A: Regulatory documents state that Dolsic is not approved for the treatment of depression. The medication is officially indicated as an analgesic (pain reliever) and antipyretic (fever reducer) for conditions associated with pain and fever.

Q: Can I take Dolsic every day for a long period?

A: According to the official product information, Dolsic is generally intended for temporary relief of symptoms. Official product labeling advises against use for pain for more than 10 days or for fever for more than 3 days without consulting a healthcare professional. Prolonged use without medical guidance is not recommended.

Q: What is the role of Dolsic's antihistamine component?

A: The official product information states that Dolsic contains an antihistamine, which helps reduce the effects of the natural chemical histamine in the body. This component helps to relieve common cold or seasonal allergy symptoms, such as runny nose, watery eyes, and sneezing, in addition to the medication's primary action on pain and fever.

Q: Can Dolsic cause liver damage?

A: Regulatory documents state that Dolsic contains acetaminophen, and exceeding the recommended dose can lead to severe liver damage or death. The risk may be increased if a person regularly consumes three or more alcoholic drinks daily or takes other medicines containing acetaminophen. Consulting a healthcare professional and carefully following the directions on the product label is essential to help manage risk.

Q: Is Dolsic safe to take during pregnancy or while breastfeeding?

A: According to the official product information, it is not definitively known whether Dolsic will harm an unborn baby or pass into breast milk. Furthermore, antihistamines may potentially slow breast milk production. Regulatory information highlights that consulting a healthcare professional for advice is necessary before using this medicine during pregnancy or while breastfeeding.

Q: Will Dolsic cause drowsiness or affect my ability to drive?

A: Official information indicates that Dolsic may cause drowsiness, dizziness, or blurred vision. This potential effect can impair judgment and motor skills. For this reason, official information advises individuals to use caution when driving or operating machinery until they know how Dolsic affects them.

Q: Is there a risk of a severe allergic skin reaction with Dolsic?

A: Regulatory warnings mention that, in rare cases, the acetaminophen component of Dolsic may cause a severe skin reaction that can be life-threatening. Symptoms to watch for include a rash that spreads and causes blistering or peeling. The official label indicates that if such a reaction occurs, the use of Dolsic should be stopped and immediate medical attention should be sought.

How to Store and Dispose of Dolsic (Tramadol Hydrochloride)

Storage and disposal must strictly adhere to regulatory requirements to ensure product stability and prevent accidental ingestion.

---

Official Storage Conditions

Requirement	Description
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Child Safety	Must be kept out of the sight and reach of children and away from pets to prevent potentially fatal accidental ingestion.
Handling	Extended-release tablets must be swallowed whole and must not be cut, crushed, chewed, or dissolved.

---

Disposal Instructions

Expired or unused Dolsic should be disposed of through a government-authorized drug take-back program. If a take-back program is unavailable, the medicine must be mixed with an undesirable substance, placed in a sealed container, and discarded in the household trash. The product must not be flushed down the toilet or poured down a drain.